| Title |
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice
|
|---|---|
| Published in |
Current Diabetes Reports, April 2017
|
| DOI | 10.1007/s11892-017-0859-2 |
| Pubmed ID | |
| Authors |
Kishore M. Gadde, Y. Pritham Raj |
| Abstract |
This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies-lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg-which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. Weight loss achieved by currently approved drugs ranges from approximately 3 to 9%, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 38% |
| Ecuador | 1 | 13% |
| Denmark | 1 | 13% |
| Mexico | 1 | 13% |
| Unknown | 2 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 50% |
| Scientists | 2 | 25% |
| Practitioners (doctors, other healthcare professionals) | 2 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 95 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 21% |
| Student > Master | 13 | 14% |
| Researcher | 12 | 13% |
| Student > Ph. D. Student | 12 | 13% |
| Student > Doctoral Student | 5 | 5% |
| Other | 10 | 11% |
| Unknown | 23 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 12% |
| Agricultural and Biological Sciences | 7 | 7% |
| Nursing and Health Professions | 6 | 6% |
| Psychology | 4 | 4% |
| Other | 10 | 11% |
| Unknown | 24 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2021.
All research outputs
#4,312,329
of 23,905,714 outputs
Outputs from Current Diabetes Reports
#224
of 1,026 outputs
Outputs of similar age
#73,910
of 311,493 outputs
Outputs of similar age from Current Diabetes Reports
#7
of 20 outputs
Altmetric has tracked 23,905,714 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,026 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,493 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.